Onco-Innovations Limited (NEO:ONCO)

Canada flag Canada · Delayed Price · Currency is CAD
1.670
+0.050 (3.09%)
At close: Nov 28, 2025
Market Cap91.01M
Revenue (ttm)84.79K
Net Income (ttm)-10.83M
Shares Out56.18M
EPS (ttm)-0.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume99,649
Average Volume29,143
Open1.620
Previous Close1.620
Day's Range1.600 - 1.700
52-Week Range0.560 - 2.800
Betan/a
RSI47.63
Earnings DateDec 12, 2025

About Onco-Innovations

Onco-Innovations Limited, a pre-clinical stage biotechnology company, develops drug candidates for cancer treatments. The company’s lead product candidate is ONC010, a novel inhibitor of the DNA repair enzyme a Polynucleotide Kinase 3′-Phosphatase (PNKP) in a nanoparticle formulation based on the drug delivery technology. Onco-Innovations Limited is headquartered in Calgary, Canada. [Read more]

Industry Biological Products, Except Diagnostic Substances
CEO Thomas O’Shaughnessy
Employees 1
Stock Exchange Cboe Canada
Ticker Symbol ONCO
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.